Cellular Biomedicine Group Launches Development Program for Asthma Stem Cell
PALO ALTO, Calif., March 17, 2014 (GLOBE NEWSWIRE) -- Cellular Biomedicine
Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new
treatments for degenerative and cancerous diseases, today announced the launch
of their pre-clinical study on human adipose derived mesenchymal progenitor
cell (haMPC) therapy for asthma. The study will evaluate the safety and
efficacy of haMPCs to treat severe asthma.
The pre-clinical study will be conducted by Shanghai First People's Hospital,
a leading teaching hospital affiliated with Shanghai Jiaotong University.
Professor Zhou Xin, director of the hospital's respiratory department and
chairperson of Respiratory Diseases Division of Shanghai Medical Association,
will lead the study as Principal Investigator.
Dr. Wei (William) Cao, Chief Executive Officer of Cellular Biomedicine Group,
Inc., commented, "Asthma places a significant burden on families and
communities in China. With 300 million people worldwide and over 30 million
people in China suffering from asthma without effective therapies, this
disease represents a meaningful unmet medical need. We are very excited to be
developing a cellular medicine solution that may have the potential to improve
the quality of life for millions of people in China and globally."
About Asthma in China
Respiratory diseases account for 15% of deaths in China. China has the largest
asthmatic population in the world and is one of the countries with the highest
asthma mortality rate. (Source: Respirology 2013, Asian Pacific Society of
Respirology) Asthma is a chronic disease of the air passages of the lungs that
inflames and narrows them, with symptoms of wheezing, breathlessness, coughing
and/or chest tightness. The disease can have a severe impact on quality of
life and can be a life-threatening disease if not properly managed.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the
treatment of certain degenerative diseases and cancers. Our developmental
stem cell, progenitor cell, and immune cell projects are the result of
research and development by scientists and doctors fromChinaandthe United
States. Our flagship GMP facility, consisting of eight independent cell
production lines, is designed, certified and managed according to U.S.
standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
Statements in this press release relating to plans, strategies, trends,
specific activities or investments, and other statements that are not
descriptions of historical facts may be forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking information is inherently
subject to risks and uncertainties, and actual results could differ materially
from those currently anticipated due to a number of factors, which include,
but are not limited to, risk factors inherent in doing business.
Forward-looking statements may be identified by terms such as "may," "will,"
"expects," "plans," "intends," "estimates," "potential," or "continue," or
similar terms or the negative of these terms. Although CBMG believes the
expectations reflected in the forward-looking statements are reasonable, they
cannot guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to update
these forward-looking statements other than as required by law.
CONTACT: Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064
Managing Director Investor Relations, Grayling
+1 646 284-9427
Director Investor Relations, Grayling
+1 646 284-9426
Cellular Biomedicine Group Inc. Logo
Press spacebar to pause and continue. Press esc to stop.